FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 349:2087-2089 November 27, 2003 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Forastiere, A. A. PubMed Citation

Every year in the United States, approximately 9500 new cases of laryngeal cancer are diagnosed, and 3800 patients die of this tumor. Persistent hoarseness is a warning sign that can lead to the detection of the tumor at an early stage. Such small tumors (stage T1 or T2, N0, and M0, according to the tumor–node–metastasis staging system) are treatable with radiotherapy alone or with modern surgical techniques, both of which can eradicate the tumor as well as preserve vocal quality. More advanced laryngeal cancers (stage III or IV) extend beyond the vocal cords into supraglottic structures, the thyroid cartilage, or . . . [Full Text of this Article]

Source Information

From the Department of Medicine, Section of Hematology–Oncology (E.E.V.), the Department of Surgery, Section of Otolaryngology–Head and Neck Surgery (K.M.S.), and the Cancer Research Center (E.E.V., K.M.S.), University of Chicago, Chicago.

Related Letters:

Nonsurgical Treatment of Laryngeal Cancer
Weinstein G. S., Myers E. N., Shapshay S. M., Colvett K. T., Gupta T., Agarwal J., Lashkar S. G., Langer M., Guntinas-Lichius O., Haddad R. I., Tishler R. B., Posner M. R., Forastiere A. A., Pajak T. F., Maor M., Weber R.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:1049-1053, Mar 4, 2004. Correspondence

This article has been cited by other articles:

• Handra-Luca, A., Hernandez, J., Mountzios, G., Taranchon, E., Lacau-St-Guily, J., Soria, J.-C., Fouret, P. (2007). Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Clin. Cancer Res. 13: 3855-3859 [Abstract] [Full Text]  
• Choe, M. S., Zhang, X., Shin, H. J. C., Shin, D. M., Chen, Z. (2005). Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Molecular Cancer Therapeutics 4: 1448-1455 [Abstract] [Full Text]  
• Weinstein, G. S., Myers, E. N., Shapshay, S. M., Colvett, K. T., Gupta, T., Agarwal, J., Lashkar, S. G., Langer, M., Guntinas-Lichius, O., Haddad, R. I., Tishler, R. B., Posner, M. R., Forastiere, A. A., Pajak, T. F., Maor, M., Weber, R. (2004). Nonsurgical Treatment of Laryngeal Cancer. NEJM 350: 1049-1053 [Full Text]